德琪医药-B2024 年度报告

(於開曼群島註冊成立的有限公司)股票代號: 6996 2024年度報告 24691226306280126131132133134135137 John F. Chin20248 1 20246 14 Maples Corporate Services LimitedPO Box 309, Ugland HouseGrand Cayman, KY1-1104Cayman Islands Rafael Fonseca 1065SOHOB1206-1209 Rafael Fonseca 110 Rafael Fonseca 881739901 Rafael Fonseca20246 14 97927 Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands 183171712-1716 6996 www.antengene.comwww.antengene.cn 839 20201120 2025613 717710 161 3 * ** 2023123167.324.72024123192.036.7%27.4%®202312 20231231115.866.92024123148.9 20231231405.7146.820241231258.9 20231231192.7119.02024123173.72024®3692.HK 20231231148.141.820241231106.3 20231231581.2261.920241231319.3 20231231533.9229.320241231304.642.9% 20241231 •ATG-010XPOVIO®®XPO1 •20246(NHIS)®(rrMM)202471® •20247(NMPA)®B(rrDLBCL) •20248(Malaysian National Pharmaceutical RegulatoryAgency)®(NDA)(1)(MM)(2)MM(PI)(IMiD)CD38MMMM •20249(Thailand Food and Drug Administration)®NDA(1)MM(2)MMPIIMiDCD38MMMM •202410(MFDS®MM(sNDA) •202411rrDLBCL®20242024202511 OnatasertibATG-008 mTORC1/2 •20245I/IITORCH-22024(ASCO 2024)ATG-008PD-1(CPI)(ORR)53.3%(DCR)86.7%ATG-008 ATG-022Claudin 18.2 •20243ATG-022IICLINCH•202512025(ASCO GI 2025)ATG-022I/IICLINCH ATG-031CD24 •ATG-031IPERFORM •20246IPERFORM2024(ASCO 2024) ATG-037CD73 •ATG-037ISTAMINA ATG-101PD-L1/4-1BB •ATG-101B(B-NHL)IPROBE-CNPROBE •20243ATG-101ATG-101PD-L1×4-1BBPD-L1PD-L1 4-1BB ATG-042PRMT5-MTAATG-201 (CD19 x CD3 TATG-102LILRB4 x CD3 TATG-106CDH6 x CD3 TATG-107FLT3 x CD3 TATG-110LY6G6D x CD3 T 2+1TAnTenGagerTMT(CRS) AIDeepSeekT(TCE) •• 20241231 20242025 ATG-022 2024ATG-022Claudin 18.2(ADC)20251ASCO GI 2025ATG-022ATG-022Claudin 18.2ATG-022Claudin 18.2ADCATG-022ATG-0222025ATG-022Claudin 18.2 •ATG-037CD732024(ESMO)I/II2025 •ATG-031CD24CD24-Siglec10ATG-031 AnTenGager™ TCE 2.0 2024AnTenGager™2+1T(TCE) 2.0TCE(CRS)AnTenGager™CD3TCETCRS AnTenGager™ TCECD32025AnTenGager™ATG-201 (CD19 x CD3)T 2024®® ®® 2025900ESGESG 2025ATG-022AnTenGager™ 20172024ATG-022AnTenGager™ 2025321 2017 15®NDA 2024 ATG-010XPOVIO®®XPO1 ®(SINE)Karyopharm Therapeutics Inc.Karyopharm® Karyopharm201973(FDA)®PIIMiDCD38 2020622®FDArrDLBCLB20201218FDA®MM 20217MFDS®PIIMiDCD38NDAB202112MFDSsNDA®MFDS202410sNDA 202112NMPA®PIIMiDCD38 20236®(XVd)(PBS) 20237®NDA(Xd)PIIMiDCD38 20238®®®200100100535® 202312®NDA(Xd)PIIMiDCD38 202312®PIIMiDCD38202411202411rrDLBCL®2024202511 20246(NHIS)®(rrMM)202471® 20247NMPA®rrDLBCL 202489®MMNDA 20241231®NDA®(Xd)(XVd)PBS®(Xd)rrMM ® •IIIBENCH •R-GDPrrDLBCLII/IIIKaryopharm(XPORT-DLBCL-030) ATG-008onatasertib mTORC1/2 ATG-008 (onatasertib)Celgene CorporationonatasertibonatasertibPD-1I/IITORCH-2 20245I/IITORCH-2ASCO2024 ATG-008 (ONATASERTIB) ATG-022Claudin 18.2202212HRECATG-022 I2023320233NMPAIND2023520235ATG-022FDAODD2024ATG-022II ATG-037CD7320222(HREC)I20226NMPA202211ATG-037 I2023720241231STAMINA ATG-031CD2420235FDAINDB-NHLPERFORM I20231220241231 ATG-101PD-L1/4-1BB20223ATG-101INMPA(IND)2022820229ATG-101FDA(ODD) ATG-042PRMT5-MTAATG-042IND(CTA) ATG-201CD19 x CD3 TATG-201IND/CTA AnTenGagerTM TAnTenGagerT AIDeepSeekTCE 2024123199ATG-010XPO1ATG-008onatasertibmTORC1/2ATG-101PD-L1/4-1BBATG-037CD73ATG-022Claudin 18.2ATG-031CD24®2023PIIMiDCD382023202411NMPA20246®rrDLBCL2024202511 2024123120231231249.6374.620241231(PCT)3PCT3 20251ASCO GI 2025ATG-022I/IICLINCH2024112221Claudin 18.2(CLDN18.2)(IHC)2+≥20%ORR42.9%DCR 95.2%1.8 – 2.4 mg/kg10CLDN18.2IHC 2+ < 20%ORR30.0%DCR50.0% 20252®(XVd)202531® 20253(BPOM)®NDA(1)MM(2)PIIMiDCD38rrMM(3)rrDLBCLB 2021®ATG-010NDA20222023202420252024BNDA NDA® 20241231 2023123167.324.72024123192.036.7%2023123127.4%®2023122023123185.7% 20231231115.866.92024123148.92024123120231231 20231231405.7146.820241231258.9(i)97.3(ii)202412312023123142.2 20231231192.7119.02024123173.7(i)2024123157.4(ii)57.020238 20231231148.141.820241231106.3 20241231 2024123114227 20241231900.1202312311,187.7 20241231 20241231956.2900.156.120241231146.3119.020.07.3 100%20241231653.4%20231231650.6% 100%2024123136.7%2023123129.1% 2024123120241231 20241231 20241231 2024123142.5 6020188282020818 3070 2001820012Johnson & Johnson Pharmaceutical Research &Development, L.L.C.20064200810Novartis AGNOVN.SIXNVS.NYSENovartis Oncology20081020173CelgeneBMY.NYSE®POMALYST®IDHIFA®201411202012201742022224SanReno Therapeutics Holding Limited 19897199412006 43202068202161820206 20200462008112012820176Pine River Capital Management201782019820191020206BFAM Partners(Hong Kong) Limited 20045201511 502020119 199972002720053200812McKinsey &Company20091201032010420121Boehringer Ingelheim Pharmaceutical Co.,Ltd.20121201312Fidelity Growth PartnersAsia20142201810FountainVest Capital2018102023122024 199671999720045 422020119 20057200772007720119201110201252013120161200820163201762017920197Canada Tenkey Holdings20182Sheng Qian Plus Corp 200572015120126201492018620187 Rafael Fonseca582023414 FonsecaGetz